TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00340704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: oral
Study: NCT04283539

Intervention type: DRUG
Intervention: systemic corticosteroid or biologic
Description: Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)
Study: NCT04492059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction augmented physical therapy
Description: Using a blood flow restriction cuff during physical therapy. It is a pressurized cuff that is used to decrease the amount of oxygen that is available to the muscle during exercise. This stimulates the muscle to believe it is in an anoxic state and can produce greater strength and hypertrophy with fewer reps and less weight which would mean less stress on a surgically repaired tendon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Completing traditional physical therapy.
Study: NCT02018653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Alumina-Silicate (CASAD)
Description: 1 gram by mouth every 6 hours for up to 6 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 by mouth every 6 hours for up to 6 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completion at baseline about diarrhea and other symptoms.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire
Description: Questionnaire completion at baseline about diarrhea and other symptoms.
Study: NCT00567840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg, 600 mg, 100 mg, 1200 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg, 600 mg, 100 mg, 1200 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg, 600 mg, 100 mg, 1200 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg, 600 mg, 100 mg, 1200 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PA-824
Description: 200 mg, 600 mg, 100 mg, 1200 mg qd
Study: NCT02134938

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Konjac Glucomannan
Description: Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
Study: NCT04529239

Intervention type: DEVICE
Intervention: Abbott Freestyle Libre Pro
Description: Continuous glucose monitoring device to analyze diabetes biomarkers.

Intervention type: DEVICE
Intervention: Abbott Freestyle Libre Pro
Description: Continuous glucose monitoring device to analyze diabetes biomarkers.
Study: NCT01675674

Intervention type: OTHER
Intervention: Dried blood spot test for MPS
Description: The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
Study: NCT03670511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sit-to-stand test
Description: to sit and stand from a chair

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: six minute walking test
Description: to walk for six minutes
Study: NCT00184002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
Description: Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles.
Study: NCT00556257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690-,550
Description: CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
Study: NCT03291951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
Study: NCT04628000

Intervention type: OTHER
Intervention: Vitamin D
Description: Clinical Correlation
Study: NCT00828061

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
Study: NCT00632645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenazine
Description: Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiapridal
Description: Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
Study: NCT02075008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 120 mg/mL solution for subcutaneous injection
Study: NCT03446209

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab Infusion RoAcemtra (EU)
Description: Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Infusion RoAcemtra (EU)
Description: Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% physiological saline
Description: Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28.
Study: NCT04053907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Case Management
Description: Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Case Management
Description: Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Case Management
Description: Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly fever screening and treatment
Description: Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly malaria screening
Description: CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDA
Description: CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
Study: NCT01327092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury Intervention Group
Description: The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
Study: NCT03061578

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Film Imager
Description: Ocular surface imaging assessment by the Tear Film Imager (TFI)

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Film Imager
Description: Ocular surface imaging assessment by the Tear Film Imager (TFI)

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Film Imager
Description: Ocular surface imaging assessment by the Tear Film Imager (TFI)

Intervention type: DIAGNOSTIC_TEST
Intervention: Low Humidity Environmental Exposure Chamber (LH-EEC)
Description: Subjects will enter the LH-EEC (\<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.

Intervention type: DIAGNOSTIC_TEST
Intervention: Low Humidity Environmental Exposure Chamber (LH-EEC)
Description: Subjects will enter the LH-EEC (\<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.

Intervention type: DIAGNOSTIC_TEST
Intervention: Low Humidity Environmental Exposure Chamber (LH-EEC)
Description: Subjects will enter the LH-EEC (\<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.
Study: NCT01155349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InSight
Description: A cognitive intervention designed to enhance speed of visual processing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No contact-control group
Description: No contact-control group.
Study: NCT03852186

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Group based psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Group based psychotherapy
Study: NCT00694356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion
Study: NCT05573438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group fructose
Description: Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Sucrose
Description: Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
Study: NCT05573438

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group Glucose
Description: Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
Study: NCT04457401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This probiotic is commercially available and contains Bifidobacterium (3 x 10\^9 colony forming units/capsule) as the active ingredient and potato starch, magnesium stearate and ascorbic acid as excipients.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains potato starch, magnesium stearate and ascorbic acid.
Study: NCT00455221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bcr-abl multipeptide vaccine
Description: The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cytokine gene adjuvant
Description: Cytokine gene adjuvant
Study: NCT00823953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Momordica charantia
Description: escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: starch powder
Description: The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
Study: NCT02839005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous suture with polyglecaprone 25
Description: At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyglecaprone 25

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous suture with polyamide (nylon)
Description: At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyamide (nylon)
Study: NCT00500968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: ERCP guided stent insertion before transection of the gland

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal pancreatectomy
Description: conventional distal pancreatectomy
Study: NCT00675532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Counseling
Description: Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy
Description: Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
Study: NCT02849470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal Injection in hair loss
Description: Comparative Injection of Control (PRP \& Acel) in hair loss; 2) Intradermal Injection in hair loss

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal Injection in hair loss
Description: Comparative Injection of Control (PRP \& Acel) in hair loss; 2) Intradermal Injection in hair loss

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal Injection in hair loss
Description: Comparative Injection of Control (PRP \& Acel) in hair loss; 2) Intradermal Injection in hair loss

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Growth factors and cytokines to promote healing and vascular supply

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Growth factors and cytokines to promote healing and vascular supply

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Growth factors and cytokines to promote healing and vascular supply

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose Derived Stem/Stromal Cells
Description: Harvesting Adipose Lipoaspirate with Microcannula System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose Derived Stem/Stromal Cells
Description: Harvesting Adipose Lipoaspirate with Microcannula System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem/Stromal Cellular Isolation (Digestive)
Description: Cell isolation and concentration add back to AD-stem/stromal cells utilizing Centricyte 1000 Protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MatriStem Matrix (ACell) - Current Standard of Care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HD-PRP (High Density Platelet Rich Plasma)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HD-PRP (High Density Platelet Rich Plasma)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HD-PRP (High Density Platelet Rich Plasma)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emulsified AD-tSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emulsified AD-tSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emulsified AD-cSVF
Description: Stem/Stromal Cellular Isolate Added Back to Emulsified AD-tSVF
Study: NCT02868840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: exercise twice a week each for one hour
Study: NCT04024956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sealing Device
Description: The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
Study: NCT03543956

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire
Study: NCT02811809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg (4 60mg tablets) daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHT
Description: Leuprolide 3-month depot 22.5 intramuscular dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IHT
Description: Leuprolide 3-month depot 22.5 intramuscular dose
Study: NCT02471066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: * Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~* Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: * Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~* Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session
Study: NCT03530956

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Mimicking Prosthetic Foot prototype 4+
Description: The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Mimicking Prosthetic Foot prototype 4+
Description: The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)
Study: NCT01200472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical to apremilast
Study: NCT02309749

Intervention type: OTHER
Intervention: CAP
Study: NCT01781065

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation